Skip to main content

Nasdaq Markets

Bristol-Myers: FDA To Review BLA For Liso-cel - Quick Facts

6 years 9 months ago
(RTTNews) - Bristol-Myers Squibb Company (BMY) announced the U.S. FDA has accepted for Priority Review its Biologics License Application for lisocabtagene maraleucel, or liso-cel, for adult patients with Relapsed or Refractory Large B-Cell Lymphoma. Liso-cel is an investigationa
Checked
2 minutes 41 seconds ago
This feed is responsible for generating the rss feed related to the topic Markets
Subscribe to Nasdaq Markets feed